Key Highlights
- Replimune shares surged 107% after an FDA advisory committee voted 10-3 that RP1's melanoma trial results were evaluable and clinically meaningful, though the vote is not binding.
- The rally mostly reversed a 30% drop from two days earlier when FDA's briefing document questioned the trial's data, calculating a 15.7% response rate versus the company's reported 33.6%.
- RP1 has already received two complete response letters, and a third FDA decision is due August 2, 2026, with cash runway extending only into early 2027.
A vote that reversed a week of losses
On the evening of Thursday 30 July 2026, the Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee voted 10 to 3 that the efficacy results from Replimune's ( Nasdaq :REPL) IGNYTE trial are, in the committee's words, evaluable and clinically meaningful. The following session Replimune shares closed at $11.20, up 107.02% from $5.41, on 33.63 million shares: roughly five times normal Volume .
The doubling looks less dramatic in context. Two days earlier the FDA had published its briefing document for the meeting, and the stock fell roughly 30%. The panel vote did not create value so much as return the shares to where they traded in mid-July, around $11. The 52-week range spans $1.50 to about $12.50.
Market Capitalisation at the close was approximately $941 million across 83.9 million shares outstanding. Wedbush lifted its rating to Outperform the same day, raising its target from $9 to $12.
What Replimune is
Founded in 2015 and based in Woburn, Massachusetts, Replimune develops oncolytic immunotherapies built on what it calls the RPx platform, a proprietary strain of herpes simplex virus engineered to kill tumour cells in a way that provokes a systemic immune response. The lead candidate, RP1 or vusolimogene oderparepvec, is injected directly into tumours and armed with a fusogenic protein and GM-CSF. Bristol Myers Squibb supplies nivolumab for the combination trials; Replimune retains full commercial rights.
Behind RP1 sit RP2, which additionally expresses an anti-CTLA-4 molecule and is in a randomised Phase 2/3 trial in metastatic uveal melanoma, and earlier work in hepatocellular carcinoma partnered with Roche. The company has no product Revenue .
The regulatory history matters more than the vote
This is the third time RP1 has come before the agency. The FDA issued a complete response letter in July 2025, concluding that IGNYTE was not an adequate and well-controlled investigation and that the trial could not be interpreted because of patient-population heterogeneity. A resubmission drew a second complete response letter on 10 April 2026, which added that the trial was not designed to isolate RP1's contribution when given with nivolumab.
Replimune's response to that second rejection was severe: Job eliminations, a substantial scaling back of US Manufacturing , and a statement that RP1 development would not be viable without Accelerated Approval . A third resubmission was accepted on 26 June 2026 under a two-month Class 1 review, with an action date of 2 August 2026.
The IGNYTE data, and the FDA's re-cut of it
IGNYTE was a single-arm, open-label trial in 140 patients with advanced melanoma who had progressed on at least eight weeks of anti-PD-1 therapy. Replimune reports an objective response rate of 33.6% by modified RECIST criteria under blinded independent review, a 15% complete response rate, median duration of response of 24.8 months and median overall survival of 32.9 months, with 47.8% of treated patients alive at three years. Grade 3-4 treatment-related adverse events occurred in 12.8%.
The agency's briefing document reached a different number. Excluding lesions that had been directly injected, FDA calculated an objective response rate of 15.7%, with a confidence interval of 10.1% to 22.8%. It noted that more than half of the company-reported responders had no non-injected target lesions at all, which goes directly to whether RP1 produces the systemic effect the company claims. Reviewers also flagged complete responses apparently reclassified after biopsies or resections, and lesions re-injected before independent review had called progression.
FDA raised a further point that is easy to overlook. In CERPASS, a separate trial of RP1 with cemiplimab in cutaneous squamous cell carcinoma, the combination failed to show a statistically significant improvement in response rate. That failure is the agency's evidence that the oncolytic component may not be contributing what Replimune attributes to it.
The financial position
For the fiscal year ended 31 March 2026, Replimune reported Research and Development expense of $221.2 million, general and administrative expense of $98.7 million, and a net loss of $313.9 million, or $3.38 a share. Cash, equivalents and short-term investments stood at $268.9 million. Non-current long-term Debt was $83.3 million, up from $46.4 million a year earlier, under a Hercules Capital Facility amended in January 2026 to defer Amortisation to October 2027.
Management guided that existing cash funds operations into the first quarter of calendar 2027, and stated explicitly that the figure excludes any potential revenue. From the catalyst date that is roughly two to three quarters of runway.
The bull case
A 10-3 vote against the review division's own recommendation is a meaningful signal, and it came from a committee that heard the injected-lesion argument in full and was not persuaded. The unmet need is real: patients who progress on anti-PD-1 therapy have few Options , and response rates on retreatment are in the single digits. Median overall survival of 32.9 months is difficult to explain away entirely as trial artefact. If approval follows, Replimune holds full commercial rights to a first-in-class product.
The bear case
Advisory committee votes do not bind the FDA, and this agency has already rejected this application twice over the sponsor's objections. The panel answered a narrow question about whether the data are evaluable and clinically meaningful; it did not resolve the contribution-of-components problem the April letter identified. If the FDA approves but adopts its own 15.7% response rate in the label, the commercial positioning against a competitor with a comparable figure weakens considerably.
Any approval would also be accelerated and conditional on IGNYTE-3, a roughly 400-patient randomised trial with overall survival as its primary endpoint that is still enrolling, a multi-year obligation on a company that cut headcount and manufacturing four months ago. And the financing question is live: a company burning over $300 million a year with runway into early 2027 has an obvious incentive to raise Equity into strength.
Valuation
No price-to-earnings or price-to-sales multiple applies: Replimune has no product revenue and posted a $313.9 million net loss. What the $941 million market capitalisation represents is a probability-weighted view of RP1 in second-line melanoma, less roughly $83 million of debt plus $268.9 million of cash. The share price moved from $11 to $5.41 to $11.20 within four sessions on no change in the underlying data, a fair indication of how wide the market's confidence interval on that probability is.
What to watch
The rally was a genuine response to a genuine event, but it repriced a binary that resolves almost immediately. The FDA's target action date is 2 August 2026. A third complete response letter would land on a company that has already said the programme is not viable without accelerated approval. An approval would raise a second question straight away: what response rate appears in the label, and whether it is the company's 33.6% or the agency's 15.7%.
Key Investor Takeaways
- The vote is advisory, not binding: The Cellular, Tissue and Gene Therapies Advisory Committee voted 10-3 in Replimune's favour on 30 July 2026, but the FDA is not obliged to follow it and has issued two complete response letters on this application already.
- The rally recovered a loss rather than breaking new ground: Shares fell roughly 30% when FDA's briefing document was published two days before the meeting; the 107% gain returned the stock to roughly its mid-July level of about $11.
- Two very different efficacy numbers are in play: Replimune reports a 33.6% objective response rate from IGNYTE. FDA's analysis excluding injected lesions produced 15.7%, with more than half of company-reported responders having no non-injected target lesions.
- The decision date is immediate: The Class 1 resubmission carries an FDA target action date of 2 August 2026; within days of the panel vote.
- Runway is finite and management has already retrenched: Cash of $268.9 million at 31 March 2026 funds operations only into the first quarter of calendar 2027, excluding revenue, against a fiscal 2026 net loss of $313.9 million. The company cut jobs and scaled back US manufacturing after the April 2026 rejection.
- Approval would be the start of a longer obligation: Any accelerated approval would be contingent on IGNYTE-3, a roughly 400-patient randomised confirmatory trial with overall survival as its primary endpoint, still enrolling.
Upcoming Catalysts
- FDA target action date for BLA 125827 (RP1 in combination with nivolumab, advanced melanoma). 2 August 2026, publicly confirmed in the company's 26 June and 30 July 2026 announcements.
- The content of any approved label, in particular whether the objective response rate stated reflects the company's 33.6% figure or the FDA's injected-lesion-excluded 15.7%.
- IGNYTE-3, the randomised Phase 3 confirmatory trial of roughly 400 patients with overall survival as the primary endpoint. Actively enrolling as of 29 June 2026. No topline readout date has been disclosed.
- REVEAL (RP2-202) in metastatic uveal melanoma; the company has guided to a Phase 2/3 transition in the first quarter of calendar 2027.
- Fiscal first-quarter results for the period ended 30 June 2026; no date announced as of 1 August 2026; the equivalent prior-year quarter was reported on 7 August 2025.
- Any Equity Financing , which management's own runway guidance into the first quarter of calendar 2027 makes a live possibility.
Principal Risks
- Binary Regulatory Risk concentrated in a single asset: management stated in April 2026 that RP1 development would not be viable without accelerated approval.
- The advisory committee vote does not bind the FDA, whose review division has twice concluded the evidence is insufficient to establish substantial evidence of effectiveness.
- Label risk: if the FDA adopts its injected-lesion-excluded response rate of 15.7% rather than the company's 33.6%, commercial positioning against existing options weakens materially.
- Trial-design objections remain unresolved. IGNYTE was single-arm with no concurrent control, and the FDA has said it was not designed to isolate RP1's contribution alongside nivolumab.
- Data-integrity questions raised in the FDA briefing document, including complete responses apparently reclassified after biopsies or resections and lesions re-injected before independent review determined progression.
- The CERPASS trial of RP1 with cemiplimab in cutaneous squamous cell carcinoma failed to show a statistically significant response-rate improvement, which the agency cites as evidence the oncolytic may not contribute as claimed.
- Funding risk: cash of $268.9 million against a $313.9 million annual net loss, with runway guided only into the first quarter of calendar 2027 and excluding any revenue.
- Debt terms: non-current long-term debt of $83.3 million under a Hercules Capital facility, with incremental tranches tied to post-approval milestones and amortisation beginning October 2027.
- Operational capability was reduced in April 2026 through job eliminations and a substantial scaling back of US manufacturing, ahead of any potential launch.
- Competition from Iovance's Amtagvi (lifileucel), already approved in advanced melanoma after anti-PD-1 therapy, with a reported response rate of roughly 30%.
- Extreme share-price Volatility : a 30% fall on a briefing document and a 107% rise on a non-binding vote within the same week, against a 52-week range of $1.50 to roughly $12.50.
Conclusion
Replimune's 107% rally was a genuine reaction to a real advisory vote, but it repriced a binary outcome that resolves within days, not a resolved question. The FDA has already rejected RP1 twice, and its own briefing document calculated a response rate less than half of what Replimune reported. With cash funding operations only into early 2027 and a third decision due August 2, the stock remains a high-stakes bet on regulatory interpretation rather than a settled story.
This article is for informational purposes only and does not constitute Investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...